
Conference Coverage
about 3 hours ago
Pharmacists Key to Mavacamten REMS, Interaction Checks in TeensLatest News

FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for gMG

Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss

SNO 2026: Vorasidenib Updates Highlight Seizure Control in IDH-Mutant Glioma

Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia

FDA Approves Pertuzumab Biosimilar for HER2-Positive Breast Cancer
Shorts










Continuing Education
All News

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.

How should a factor XIa inhibitor be incorporated into secondary stroke prevention?

Inconsistent state immunization laws complicate pharmacy operations and limit patient access.

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.

No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, although HHS maintains the pilot is ongoing.

Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.

Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.

About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.

ASRA’s cancer pain programming highlights opportunities for pharmacists to individualize opioid therapy, improve medication transitions, and connect patients with evidence-based complementary care.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.

Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.

The once-daily oral CSF-1R inhibitor was approved based on the phase 3 MANEUVER trial, which showed gains in tumor response, pain, and joint function.

In an interview with Pharmacy Times, Thomas Hope, MD, discusses where peptide receptor radionuclide therapy fits in neuroendocrine tumor treatment and how pharmacists can support treatment coordination and follow-up care.

SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.

On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.

A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.


































